Ajay Devgn's Dhamaal 4 crosses Rs 125 crore as Pentagon's testosterone-testing plan draws medical pushback

On 19 July 2026, two very different stories sat on the same global news desk. In Mumbai, trade estimates put Ajay Devgn's Dhamaal 4 on course to clear the Rs 125 crore box-office mark, a milestone for one of Hindi cinema's more durable comedy franchises. Across the Atlantic, a parallel filing warned that a Pentagon plan to mandate annual testosterone screening for every US service member had drawn formal objections from physicians, who argue the protocol is medically unjustified and operationally hazardous. Read together, the items sketch a snapshot of 2026's media priorities: commercial spectacle in the world's largest film market, and a US defence-medical controversy that sits at the uneasy intersection of fitness doctrine, privacy, and force readiness.

The Indian Express trade report on 19 July at 09:52 UTC frames Dhamaal 4 as the latest instalment of a franchise that has, across two decades, built a reliable Hindi-belt audience on ensemble comedy, recurring gags, and Devgn's deadpan anchor role. Crossing Rs 125 crore, on the paper's estimate, places the film in commercially viable territory for a star-led Hindi release in 2026, even as Hindi theatrical collections continue to face structural pressure from South Indian productions, OTT windows, and a compressed theatrical calendar.

The money and the math

A Rs 125 crore net is no longer the ceiling it once was for a star vehicle, but in the current Hindi market it still signals a hit rather than a smash. The Indian Express number is a projection rather than a finalised figure, with trade analysts triangulating from multiplex chains, single-screen exhibitors, and regional circuits. Dhamaal 4 benefits from a relatively low-cost ensemble template, repeat-viewer pull across tier-2 and tier-3 cities, and a marketing cycle tied to school-holiday footfall, conditions that have, over the franchise's history, cushioned the series against the volatility that punishes newer Hindi launches.

The structural story behind the milestone is the one to watch. Hindi cinema's theatrical share has narrowed against Telugu, Tamil, and Malayalam productions that command pan-Indian and overseas footprints; the Dhamaal brand survives because it operates closer to mass-market spectacle than to prestige releases. The Indian Express coverage leans into the commercial reading. It does not engage with the deeper question of whether the franchise's audience is renewing itself or simply ageing out, a debate that has been running in trade publications for several release cycles.

The Pentagon's screening plan

The second story, filed by The Indian Express at 08:52 UTC the same morning, is more pointed. The Pentagon, the report says, is preparing to require annual testosterone tests for US service members, a sweeping screening regime that defence physicians have publicly warned against. Doctors interviewed for the piece argue that blanket annual testing is not medically indicated for the general force, that it risks misclassifying normal physiological variation as pathology, and that the resulting clinical pathway, which can include referral, retesting, and possible treatment, would consume medical capacity without a proportionate readiness benefit.

The medical counter-argument runs along familiar lines. Testosterone levels vary across age, time of day, sleep, and training cycle, and a single annual reading is a noisy measure. Endocrinologists cited in this kind of coverage typically point out that population screening for hormonal abnormalities is only cost-effective when prevalence is high and a clean intervention exists; the literature on hypogonadism in young and middle-aged men does not support mass annual screening. The piece also flags downstream effects: stigma around a low result, the possibility of disclosure into personnel records, and the operational cost of pulling service members into repeated endocrine workups.

The Pentagon's framing, where it has been reported, leans on force readiness and a desire to catch what defence officials describe as subclinical decline before it becomes a deployability issue. That case has not yet been publicly substantiated with internal data, and the absence of a published rationale is the most useful thing to note: the policy is being driven forward without the kind of independent epidemiological case that would normally accompany a service-wide screening mandate. This publication will continue to track whether the Department of Defense publishes the underlying clinical criteria, and whether the relevant Congressional committees take up the question in oversight hearings.

What the two stories share

Read separately, they are unrelated. Read together, they say something about how the global news cycle in mid-2026 parcels its attention. A Bollywood sequel's commercial milestone travels as a feel-good trade item. A Pentagon medical mandate, with implications for roughly 1.3 million active-duty service members and several hundred thousand reserve components, moves through the same wires at a slower cadence, with less column-inch per day. Both stories are sourced, both are verifiable, but the institutional weight behind the second is several orders of magnitude greater than the first.

That asymmetry is itself a story. Cultural-economy reporting in the Anglophone press treats Bollywood box-office figures with the same diligence it applies to US defence policy, but rarely with the same follow-through. A franchise like Dhamaal will get a steady drip of trade updates over its theatrical run; a service-wide hormonal screening mandate will get a cluster of articles on launch, then thin coverage unless there is a leak, a lawsuit, or a Congressional flare-up.

What to watch next

Two concrete developments will determine whether these stories hold the desk's attention. The first is Dhamaal 4's second-Saturday hold and overseas run: the Rs 125 crore projection is a mid-run estimate, and a soft second weekend, common in 2026's compressed-release calendar, would push the final net down by enough to reset the trade narrative. The second is whether the Pentagon publishes the clinical and operational rationale behind the testosterone mandate before the policy takes effect, or whether it is implemented under existing service-level authorities without a clean public case. Each outcome will tell us something about how, in 2026, the institutions that govern bodies and the institutions that govern audiences alike prefer to operate: under the lights, or behind them.

Desk note: this article pairs two items from The Indian Express' 19 July wire to flag a pattern in news-cycle weighting. The wire covers the Bollywood milestone in trade terms and the Pentagon policy in clinical terms; Monexus reads them against each other.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://en.wikipedia.org/wiki/Dhamaal_(film_series)
• https://en.wikipedia.org/wiki/Ajay_Devgn
• https://en.wikipedia.org/wiki/Hypogonadism